Back to Trial

Oracle Runs

Oracle findings and outcome history for Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V (NCT05268289).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT05268289 remains recruiting per latest sources, with primary completion estimated March 2026. No topline results, readouts, or efficacy data published. Ongoing status precludes positive/negative classification.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
Web Searchclinicaltrials.gov
ClinicalTrials.gov: NCT05268289 Study of Efficacy and Safety of LNP023 in Lupus Nephritis
Current status: Recruiting. No results posted.
Web Searchnovartis.comMar 20, 2026, 12:00 AM
Novartis Clinical Trial Page: NCT05268289
Last update Mar 20, 2026. Ongoing Phase 2 trial, no results reported.
Web Searchnovartis.comOct 28, 2024, 12:00 AM
Novartis Renal Portfolio Investor Event Oct 2024
Phase 2 (NCT05268289), trial size 240, next readout 2026.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial is still recruiting (est. primary completion 2026). No public efficacy readout, topline results, or interpretation of CRR primary endpoint found for this exact Phase 2 study (NCT05268289). Mentions of iptacopan in LN are protocol descriptions, preclinical, or for other indications (IgAN, C3G). Evidence incomplete and not trial-specific.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:19 PM
Web Searchclinicaltrials.gov
NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Current status: Recruiting. Estimated primary completion: 2026-03-30. No results posted.
Web Searchnovartis.comMar 20, 2026, 12:00 AM
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Novartis
Recruiting Phase 2 trial. No results, data or readouts available.
Web Searchnovartis.comApr 15, 2024, 12:00 AM
New Novartis Fabhalta® (iptacopan) data show clinically meaningful... IgA nephropathy (IgAN)
Positive data in IgAN (different indication); lists LN as ongoing investigational use only.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
ClinicalTrialsclinicaltrials.govMar 20, 2026, 12:00 AM
Study Details | NCT05268289 | ClinicalTrials.gov
ClinicalTrials.gov lists recruiting; primary completion 2026-03-30; hasResults=false on the latest posted update.
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout is publicly available yet. The trial record still shows recruiting status, and Novartis’ renal pipeline materials list NCT05268289 as Phase 2 with the next readout only broadly in 2026. Without a public result framed for this exact trial, direction cannot be classified.

Found Apr 3, 2026, 4:31 PMReviewed Apr 3, 2026, 4:46 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
ClinicalTrials.gov lists NCT05268289 as Phase 2 and still recruiting; no posted study results/public efficacy interpretation were identified.
Sponsornovartis.comOct 28, 2024, 12:00 AM
Novartis Renal Portfolio Investor Event
Novartis slide for lupus nephritis lists iptacopan Phase 2 trial NCT05268289 with 'Next readout 2026,' implying no public readout had occurred as of that update.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear trial-specific public efficacy readout was found. The official Novartis trial page and ClinicalTrials.gov listing still show NCT05268289 as recruiting/ongoing, so there is not enough public evidence to label this Phase 2 study positive or negative.

Found Apr 1, 2026, 7:56 PMReviewed Apr 1, 2026, 7:56 PM
Sponsornovartis.com
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Novartis
Official Novartis trial page updated Mar 20, 2026 lists Phase 2 NCT05268289 as Recruiting, with completion date Sep 28, 2028; no public efficacy results/readout are provided.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05268289 | ClinicalTrials.gov
ClinicalTrials.gov lists this exact lupus nephritis Phase 2 trial and describes the week-24 CRR primary endpoint, but the public listing does not provide a clear posted results interpretation for the study.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.